



Academy of
Managed Care
Pharmacy®

ADVANCING VALUE-BASED CONTRACTING

An AMCP Partnership Forum

JUNE 20-21, 2017 ➤ ARLINGTON, VA

Program

— Hosted by the Academy of Managed Care Pharmacy in partnership with —



Bristol-Myers Squibb



MERCK
INVENTING FOR LIFE



National
Pharmaceutical
Council



PREMIER




RxAnte
Know the future.
Then change it.



Xcenda
AmerisourceBergen



AMCP 2017 NEXUS



Changing the Way We Pay for Health Care

OCTOBER 16-19 | GAYLORD TEXAN HOTEL & CONVENTION CENTER | DALLAS

Join thousands of your fellow managed care professionals this fall in the heart of Texas for a look at how value-based health care is changing all the rules. Go inside the current health care market and the factors shaping a radically different future, one that will emphasize value and improved patient outcomes as the metrics for success. Enjoy the content and contacts that build a career, while exploring the role you and your colleagues will play in this brave new world.

***It's more than dollars and cents.
More than co-pays and risk-shares,
payers and patients.***

***And it's coming at you faster
than you think.***

www.amcpmeetings.org

AMCP | Academy of
Managed Care
Pharmacy®

WELCOME

Welcome to our AMCP Partnership Forum on Advancing Value-Based Contracting. We gather at a crucial moment in the evolution of the U.S. health care system. Since the 2010 passage of the Affordable Care Act (ACA), we have witnessed a seismic shift in how health care services are paid for: *from payment models based primarily on volume and quantity to models focused increasingly on value and quality.*

Efforts to repeal and replace the ACA, along with recent Congressional scrutiny on escalating drug costs, underscore the urgency we face in increasing the value that pharmaceuticals deliver to patients. We also must recognize that we don't have 10 years to build new processes and systems to move towards value-based care. The current system is unsustainable given the annual inflation of health care costs.

Whatever happens in Washington, our health care system must move in the direction of adopting models that pay for products and services based on how well they perform. That is why I am so delighted to convene such a diverse array of stakeholders on this topic. Your efforts will ensure that momentum continues in the adoption of value-based contracting.

Over the next two days, we will examine successes, opportunities and challenges to this model. We will seek ways to improve data validation, integration and methodologies necessary to make value-based contracting work. We will seek consensus on a definition of value-based contracting to help facilitate discussions with policy-makers and regulators. And we will develop action plans to mitigate any current and future legal and regulatory barriers.



Looking back, we've come a long way in just a relatively short amount of time. A decade ago, the idea of linking the cost of a therapy to its performance was considered revolutionary. Today, value-based care is considered a key solution to improving patient care while better managing costs.


I am proud that AMCP is at the forefront of this effort. Thank you to the sponsors of this forum: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Merck, National Pharmaceutical Council, Novo Nordisk, Pharmaceutical Research and Manufacturers of America, Premier, RxAnte, Takeda, and Xcenda. And thank you to the participants. Let's get to work!

Sincerely,

A handwritten signature in blue ink, which appears to read "Xcenda" or a stylized version of the name.

Susan A. Cantrell, RPh, CAE

Chief Executive Officer
Academy of Managed Care Pharmacy

A microscopic view of various cells, including a large cluster of spherical cells on the right and several smaller clusters and individual cells scattered on the left. The background is a dark, textured blue.

GOING
AFTER
CURES
ISN'T FOR
THE FAINT
OF HEART.

GoBoldly.com

PhRMA is proud to be a supporter of the
Academy of Managed Care Pharmacy's
2017 Partnership Forum.
Welcome to the future of medicine. For all of us.

GOBOLDLY



**America's
Biopharmaceutical
Companies™**

AGENDA

Renaissance Capital View Hotel, 2800 South Potomac Ave, Arlington, VA
Salon 1-3

TUESDAY, JUNE 20TH

7:00am – 8:00am	BREAKFAST
8:00am – 8:15am	WELCOME
8:15am – 9:00am	VALUE-BASED CONTRACTING PARTNERSHIP FORUM GOALS INTRODUCTIONS
9:00am – 9:15am	AMCP MEMBERSHIP VALUE-BASED CONTRACTING SURVEY RESULTS
9:15am – 9:45am	PRESENTATION: The Value-Based Contracting Landscape: Trends, Hurdles, Capability Frameworks
9:45am – 10:00am	BREAK
10:00am – 10:30am	PRESENTATION: Network for Excellence in Health Innovation (NEHI) White Paper <i>“Rewarding Results: Moving Forward on Value-Based Contracting for Biopharmaceuticals”</i>
10:30am – 11:30am	PANEL DISCUSSION: Practical Experiences with Value-Based Contracts
11:30am – 12:45pm	LUNCH
12:45pm – 2:00pm	BREAKOUT SESSION #1: Defining Value-Based Contracting
2:00pm – 2:15pm	BREAK
2:15pm – 3:45pm	PANEL DISCUSSION: Tackling Performance Metrics and Measures
3:45pm – 5:15pm	BREAKOUT SESSION #2: Driving Solutions to Value-Based Contracting Challenges
5:15pm – 7:00pm	DAY 1 CLOSE COCKTAIL RECEPTION

WEDNESDAY, JUNE 21ST

7:00am – 8:00am	BREAKFAST
8:00am – 8:15am	WELCOME BACK DAY 2 AGENDA
8:15am – 9:45am	BREAKOUT SESSION #3: Exploring Value-Based Contract Requirements
9:45am – 10:00am	BREAK
10:00am – 10:45am	PANEL DISCUSSION: Forging Legal and Regulatory Changes in the New Washington Landscape
10:45am – 12:15pm	BREAKOUT SESSION #4: Creating a Legal and Regulatory Action Plan
12:15pm – 12:45pm	AMCP’S PATH FORWARD FOR VALUE-BASED CONTRACTING
12:45pm	LUNCH DEPARTURE




Pioneering science delivers vital medicines™

Transforming the language of life into vital medicines

At Amgen, we believe that the answers to medicine's most pressing questions are written in the language of our DNA. As pioneers in biotechnology, we use our deep understanding of that language to create vital medicines that address the unmet needs of patients fighting serious illness – to dramatically improve their lives.

For more information about Amgen, our pioneering science and our vital medicines, visit www.amgen.com.



MODERATOR

Susan C. Winckler is the Chief Risk Management Officer, as well as a lead contributor in the firm's alliance management and regulatory consulting activities, for Leavitt Partners (LP), a health care intelligence firm. Founded by former HHS Secretary and EPA Administrator Michael O. Leavitt, LP advises senior executive teams about health care developments such as health insurance exchanges, Medicaid expansion, the conversion of fee-for-service payment to value-based payment, and helps clients navigate federal policy makers such as the Food and Drug Administration and the Centers for Medicare and Medicaid Services. From October 2014 to October 2015, she served as LP's lead staff member and the interim executive director for the Health Care Transformation Task Force, an alliance of patients, payers, providers and purchasers committed to moving 75% of their businesses to value-based payment by 2020.

From late 2009 to mid-2014, Winckler simultaneously served as a Senior Advisor with LP and as the President and Chief Executive Officer of the Food and Drug Law Institute (FDLI), a nonprofit 501(c)(3) organization committed to providing a marketplace for discussing global food and drug law issues through conferences, publications and member interaction. From January 2007 to June 2009, she served as the Chief of the Staff for the Food and Drug Administration within HHS. In that capacity, she provided integrated policy analysis and strategic consultation to the Commissioner and senior officials on significant agency issues and programs. Winckler also led the operations of the Office of Legislation, Office of External Relations, Office of Public Affairs, and Office of the Executive Secretariat.

Prior to joining FDA, Winckler was the Vice President for Policy and Communications and Staff Counsel for the American Pharmacists Association (APhA). As pharmacist and attorney by training, Winckler served as the primary spokesperson



for APhA during media interviews, and was APhA's senior lobbyist. Previous positions with the Association include Group Director, Policy and Advocacy; Director, Policy and Legislation; Director, Practice Affairs, and Manager, Special Projects. Prior to joining APhA, Winckler directed the implementation of the Iowa Medicaid Drug Prior Authorization Program for the Unisys Company, and worked for the Iowa Pharmacists Association (now the Iowa Pharmacy Association) and a community pharmacy in Iowa.

She has been recognized as a Fellow of the American Pharmacists Association, a Distinguished Alumna of the University of Iowa College of Pharmacy, a Distinguished Young Alumna by the University of Iowa Foundation, a Woman of Distinction by Alpha Xi Delta Fraternity, and elected as a Distinguished Fellow in Public Policy to the National Academies of Practice, Pharmacy Academy. She delivered the William A. Zellmer Lecture for the American Society of Health-System Pharmacists and was elected a Trustee of the United States Pharmacopeial Convention (USP) for the 2015-2020 term. Winckler is a graduate of the University of Iowa College of Pharmacy and the Georgetown University Law Center, magna cum laude. She is licensed to practice pharmacy in Iowa and admitted to the bar in the Commonwealth of Virginia.



AT BRISTOL-MYERS SQUIBB,
WE ARE WORKING TOGETHER
FOR PATIENTS

Our mission is clear — we discover, develop and deliver transformational medicines that help people prevail over serious diseases.

Our sense of urgency is real — we work every day to push the boundaries of scientific discovery and to make a meaningful difference in the lives of patients.

It's what we do. It's why we do it.



Bristol-Myers Squibb

www.bms.com

FORUM PARTICIPANTS



Amanda Bain, PharmD, MPH, MBA

*Director of Pharmacy and Care Management
The Ohio State University Health Plan*

Amanda Bain leads the creation, implementation and evaluation of nursing and pharmacy care management programs. Additionally, she acts as the clinical liaison to the Office of Human Resources, the OSU Wexner Medical Center, and the PBM vendor in support of pharmacy benefit program designs, services, and communications for The Ohio State University. She has served on numerous national committees regarding pharmacy education, quality, and technology.



Joshua S. Benner, PharmD, ScD

*President and CEO
RxAnte*

Joshua Benner's award-winning research and publications have shed new light on the problem of nonadherence and identified approaches to improving it. Prior to RxAnte, Joshua was Fellow and Managing Director at the Brookings Institution's Engelberg Center for Health Care Reform, where he focused on medical technology policy. Prior to Brookings, he was principal at ValueMedics Research, an analytic and consulting services firm. Following the sale of ValueMedics to IMS Health in 2007, he served as senior principal in health economics and outcomes research and global lead for medication adherence at IMS. Joshua received his Doctor of Pharmacy degree from Drake University and his Doctor of Science in health policy and management from the Harvard University School of Public Health.



Joel V. Brill, MD, FACP

*Chief Medical Officer
Predictive Health*

Joel V. Brill is an executive clinician with more than 30 years of experience providing strategic leadership and medical oversight to large data-driven health organizations. He is skilled in strategy, development and implementation of innovative health programs, products and payment systems, with extensive experience in clinical practice, research, coverage, reimbursement, quality improvement, bundled and episode payments and accountable care.



Diana Brixner, RPh, PhD

*Professor, Department of Pharmacotherapy
University of Utah College of Pharmacy*

Diana Brixner is Executive Director of the Pharmacotherapy Outcomes Research Center and Director of Outcomes for the Program in Personalized Health at the University of Utah. Diana has published numerous articles, authored five book chapters, has one issued patent, and has been an invited speaker at national and international meetings. She is the current AMCP President, and is past President of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). Diana has a pharmacy degree from the University of Rhode Island, and a doctorate in medicinal chemistry from the University of Utah.

A woman with dark hair, wearing safety glasses and a white lab coat, is focused on her work in a laboratory. She is holding a piece of equipment, possibly a pipette or a small container, and is looking down at it. The background is blurred, showing laboratory equipment and other people. A red curved shape is overlaid on the left side of the image.

*Hong Hu, Research Advisor,
Lilly Research Laboratories*

It begins with a promise to discover medicines that make life better.

Since 1876, we have worked tirelessly to develop and deliver trusted medicines that meet real needs, finding ways to come through no matter the odds. From the development of insulin to the discovery of new treatments for mental illness, we have pioneered breakthroughs against some of the most stubborn and devastating diseases. We bring this same determination to our work today, uniting our expertise with the creativity of research partners across the globe to keep finding ways to make life better.

To find out more about our promise, visit www.lilly.com/about.
2016 CA Approved for External Use PRINTED IN USA ©2016, Eli Lilly and Company. ALL RIGHTS RESERVED.

Lilly

FORUM PARTICIPANTS



Douglas Brown

Vice President, Account Management, Pharmacy Pricing & Value Based Solutions

Magellan Rx Management

Doug Brown oversees the Medicaid channel with operational responsibility for both of Magellan's multi-state purchasing pools: National Medicaid Pooling Initiative and The Optimal Pharmacy Solution (TOP\$). In addition to the 17 states that participate in the multi-state pools, he oversees the manufacturer contacting and Preferred Drug List design for Arkansas, Arizona, Colorado, Florida, Missouri, Tennessee, Texas and Virginia. Doug also has account management responsibility for Alaska, Idaho, Michigan, Kentucky, North Carolina and Virginia. He began his career with CVS/Pharmacy in 1988 and served as Pharmacist-in-Charge and a store manager. He has an MBA from Virginia Commonwealth University and a BS in Pharmacy from The University of Rhode Island. He is a registered Pharmacist and lives outside of Richmond, Virginia.



Ambrose Carrejo, PharmD

Director, Pharmaceutical Contracting and Strategic Purchasing

Kaiser Foundation Hospitals

Ambrose Carrejo received his Doctor of Pharmacy degree in 1986 from the University of California at San Francisco, School of Pharmacy. He began his professional career at the Pacific Presbyterian Medical Center in San Francisco where he worked as a clinical pharmacist, running the Total Parenteral Nutrition Service for Pharmacy and providing clinical services to the medical/surgical ward. He moved to Kaiser Permanente in 1990 as a Drug Education Coordinator at Kaiser Richmond. Other positions at Kaiser included Clinical Operations Manager, Drug Use Manager for Northern California, and Assistant Director of Pharmaceutical Contracting.



Tim Cernohous, PharmD, PhD

Director of Ambulatory Pharmacy Services

Essentia Health

Tim Cernohous has responsibility for 17 ambulatory pharmacies across the health system, along with Essentia Health (EH) Specialty Pharmacy, EH Prescription Service Center, the MTM program and the Patient Assistance Program. In addition, Tim continues to do research on patient incentives, evaluation of pharmacy benefit designs, as well as optimization of Essentia's population care management process. He is a graduate of the University of Minnesota, College of Pharmacy. Following his PharmD training, Tim entered the University of Minnesota graduate program completing his PhD in Social and Administrative Pharmacy with an emphasis on consumer behavior.



Joseph Coppola

Managing Director, Life Sciences Commercial Strategy & Operations Practice

Deloitte Consulting

Joseph Coppola is leader of the Commercial Operations Transformation practice as well as the Contracting Strategy/Operations and Gross-to-Net Optimization practice. He has more than 28 years of operational and technology strategy consulting experience, with 24 of them serving the life sciences industry in primarily commercial, distribution, pricing, contracting and general council functions. During his career, he has led many large-scale systems integration projects at leading life sciences companies.



MERCK

INVENTING FOR LIFE

WHY WE INVENT

AT MERCK, WE ARE INVENTING FOR LIFE.

We are not inventing for invention's sake – we are on a quest to cure – and to have an impact on countless people's lives worldwide.

Merck is inventing because the world still needs cures for cancer, Alzheimer's disease, HIV, and so many other causes of widespread suffering in people and animals.

We are taking on the world's most challenging diseases to help people go on, unburdened, to experience, create and live their best lives.

Merck. **Inventing** for Life.

To explore our commitment to invention, visit www.merck.com and connect with us on Facebook, LinkedIn and Twitter.

FORUM PARTICIPANTS



Van Crocker

President

Healthagen Outcomes,
Healthagen, a division
of Aetna

Van Crocker leads the Healthagen Outcomes unit of Healthagen, which leverages Aetna's vast member scale and broad analytical expertise to address outcomes and development challenges faced by pharmaceutical/biotech/device companies worldwide. Previously, Van led finance and business development for AuraSense, a biotechnology company. Van also has served as a management consultant with Booz & Company's Global Healthcare Practice, focusing on payer/provider/pharmacy clients. Before that, Van helped to launch NanoInk, Inc., a nanotechnology firm. Van earned an MBA with honors from the Kellogg School of Management, and received his Bachelor of Science degree in Commerce from the University of Virginia.



Bob DiRenzo

*Managing Director, Specialty
Solutions and Analytics*
Evolent Health

Bob DiRenzo is responsible for evaluating Evolent's population-health-based drug management strategies and performance, as well as serving as principal architect in building the Evolent specialty pharmacy solution. Bob has more than 17 years of experience in pharmacy benefit and specialty drug management, having served executive management and consulting roles at Pharmaceutical Strategies, Pharmacy Data Management, and Medco. Bob holds a BS in pharmacy from The Ohio State University.



Michelle Drozd

*Deputy Vice President, Policy
and Research*
Pharmaceutical Research and
Manufacturers of America
(PhRMA)

Michelle Drozd focuses on issues related to how the pharmaceutical industry is adapting to the increasingly competitive and value-based healthcare environment. Prior to joining PhRMA, Michelle managed a quality improvement team at Partners Healthcare that helped the integrated delivery system reduce readmissions, identify and manage high risk patients, conduct care management programs, improve end-of-life care, and implement a quality improvement training program. In addition, Michelle worked at RTI International on design and implementation of the Physician Group Practice demonstration, a precursor to the Medicare Accountable Care Organizations. Michelle holds a BA in economics and public policy from Duke University and a SM in health policy and management from Harvard School of Public Health.



Amy M. Duhig, PhD

*Senior Director, Global Health
Economics and Outcomes
Research*
Xcenda

Amy M. Duhig leads research at Xcenda that helps manufacturers strategically develop evidence to communicate product value to internal and external stakeholders. Prior to joining Xcenda, Amy held roles in global research departments in large pharmaceutical companies, providing strategic and tactical support within virology, endocrinology and neuroscience therapeutic areas. She has her PhD in Clinical Psychology from the University of South Florida and completed her post-doctoral work at Yale University. She has been an invited speaker at national conferences and has authored numerous peer-reviewed articles.

Can We Help Patients Through Innovative Payer-Pharma Agreements?



When payers and biopharmaceutical companies collaborate on value-based agreements, it can increase patient access to innovative treatments.

But there are operational, communications and regulatory issues that make it challenging for payers and biopharmaceutical companies to develop these agreements.

It's time to work on solutions to these challenges for the benefit of patients and our entire health care system.

Learn more about this important topic by visiting NPC's website at www.npcnow.org.



1717 Pennsylvania Avenue, NW | Suite 800 | Washington, DC 20006
202.827.2100 | www.npcnow.org | info@npcnow.org

FORUM PARTICIPANTS



Paul Eiting

Senior Manager, Value-Based Policy

Blue Cross Blue Shield Association

Paul Eiting focuses on prescription drug and FDA-related issues at BCBSA. Previously, Paul served as the Policy Director at AHIP where he was the lead analyst during federal health care reform, and managed AHIP's implementation of the Affordable Care Act. He also served as the Legislative Correspondent to Rep. Paul Ryan (R-WI), managing the member's constituent correspondence and researching policy and legislation for recommendations to the member. Paul received his undergraduate degree in political science and history from Carthage College and a master's degree in public policy from American University.



David Evans

Director, U.S. Pricing and Value Based Contracting Strategy

Merck & Co.

David joined Merck's U.S. commercial organization in 2016, currently leading a team charged with the strategic development and implementation of opportunities relating to U.S. product pricing and value based contracts. Over the past five years, David's roles at Merck included supporting global research and product development strategy in Oncology and Alzheimer's Disease, and market access and government relations roles within MSD, Merck's UK organization. Prior to joining MSD, David worked at the Wellcome Trust in London, supporting Global Health policy development. David holds a Masters in Health Economics from Erasmus University, Rotterdam, and an undergraduate degree in Biological and Biomedical Sciences from the University of Cambridge, UK.



John Fox, MD

Associate Chief Medical Officer

Priority Health

John Fox is responsible for technology assessment and medical policy development, total cost of care management, and innovations at Priority Health. His responsibilities include pay-for-value contracting, integrated specialty pharmacy management, behavioral health initiatives, community-based palliative care, and oncology medical home programs. Prior to joining Priority Health, John was the chief medical officer at Physicians Plus Insurance. He also has worked for the Indian Health Service and with the Epidemic Intelligence Service at the CDC in Atlanta. He received his medical degree from Johns Hopkins University School of Medicine and a master's degree in health administration from the University of Wisconsin.



Mary Elizabeth Gately

Partner

DLA Piper

Mary Gately is co-head of DLA Piper's Washington, D.C., Litigation group. Her practice focuses on reputation management, class actions, cross border litigation and other complex litigation in the fields of the First Amendment, product liability and commercial litigation. She has industry expertise in health care and life sciences, as well as the food and beverage sector. In March 2017, she presented the course "Expanding Drug Use Information Communication, Implications of FDAMA 114" at the University of Florida, College of Pharmacy. Mary repeatedly has been ranked by Chambers USA, and in the 2016 edition was recognized as an "outstanding" lawyer who "combines a deep understanding of legal principals with a common-sense approach to practice." She received her law degree from Harvard Law School.



UNDERSTANDING SUPPORT

passion for improving patient lives

As a leader in diabetes care, we strive to provide optimal care for patients and to put their needs at the center of everything we do.

Making a positive difference in people's lives is at the heart of everything Novo Nordisk does – through groundbreaking science, sustained focus on the environment, and patient-centered care.

For more about us, visit novonordisk.us.

FORUM PARTICIPANTS



Stephen George, PharmD

*Senior Consultant
Milliman*

Stephen George assists clients in areas such as health plan pharmacy operations, management of physician-administered and specialty drugs, and integration of pharmacy and medical outcomes analysis. Stephen has experience in various patient and management settings, including managed care, hospital, care management and clinical trials. Other experience includes health policy analysis, pharmacoeconomics and outcomes research, auditing PBM/specialty pharmacy contracts, 340-B pricing models, implementing disease management models, drug/device pricing, assessing pharmacy MTM programs, and developing “best in class” clinical applications. He received his PharmD from Broadmore University, a Masters of Science Hospital Pharmacy Administration from The Ohio State University, and a BS Pharmacy from Samford University.



Patrick Gleason, PharmD, FAMCP, FCCP, BCPS

*Senior Director, Health Outcomes
Prime Therapeutics*

Patrick Gleason leads Prime’s clinical health outcomes assessment team in the development and improvement of pharmacy benefit management programs. Through integrated medical and pharmacy claims data analysis, he assesses clinical program opportunity and post-implementation outcomes. Patrick also is an Adjunct Professor of Pharmacy at the University of Minnesota, College of Pharmacy. He is a Board Certified Pharmacotherapy Specialist, an elected Fellow of the Academy of Managed Care Pharmacy, as well as a Fellow of the American College of Clinical Pharmacy. He has over 40 peer-reviewed publications in medical and health policy journals such as Health Affairs, Journal of Managed Care Pharmacy, Medical Care, Archives of Internal Medicine, and JAMA.



Jason Harris

*Manager, Public Policy
National Health Council*

Jason Harris joined the National Health Council (NHC) in August 2016. Prior to that, he worked in the Public Policy Department at The ALS Association. Jason helps establish public policy at the NHC, which is made up of more than 100 national health-related organizations, with a core membership of 50 leading patient advocacy groups. NHC brings together diverse health care stakeholders to work for health care that meets the personal needs and goals of people with chronic diseases and disabilities. Jason earned a BA in History from the University of Maryland.



Dorothy Hoffman, MPP

*Director, Healthcare Transformation and Policy Partnerships
Eli Lilly and Company*

Dorothy Hoffman’s focus at Lilly includes value based payment models for innovative medicines, health care consumerism and affordability. Previously, Dorothy was the Head of U.S. Health Policy, where she provided strategic advice to the company’s business leadership on how legislative and regulatory changes impact the development and commercialization of Lilly’s innovative medicines portfolio. Dorothy began her career at Lilly in 2004, and has held positions of increasing responsibility at the Company Headquarters and in Lilly’s business affiliate offices in the U.S., Belgium and the UK.



EXPANDING OUR SPECIALTY PHARMACY FOOTPRINT

Commcare Specialty Pharmacy and Acro Pharmaceutical Services now work together as Premier Inc. companies.



Greater
Medication Access



Increased Access
to Payers, Patients
and Providers



Providing More
Choices for Customers

DELIVERING WHAT YOU NEED – EXCEPTIONAL SERVICE AND SUPPORT

- 24/7 Clinical Pharmacist Support
- Best-In-Class Medication Adherence Rates
- Assist Disease State Management Programs
- High Touch Personalized Patient Care
- >95 Percent Patient/Provider Satisfaction Rate
- Free and Confidential Home Delivery



888.203.7973 | www.commcarepharmacy.com



800.906.7798 | www.acropharmacy.com



FORUM PARTICIPANTS



Scott Howell, MD

*Senior Executive
Heritage Development
Organization*

Scott Howell is responsible for business development and identifying enterprise-wide clinical solutions at Heritage Development Organization. Previously, he was National Senior Medical Director and Chief Medical Officer for Network and Population Health at Optum Insight. Other prior positions include Regional Chief Medical Officer for the Northeast Region of AmeriChoice; Medical Director for Managed Care at the AIDS Healthcare Foundation; and lead scientific advisor to Management Sciences for Health, the prime contractor for the President's Emergency Plan for AIDS Relief (PEPFAR) in Haiti. In addition, Scott has served the military for 23 years and his current reserve assignment is with the Office of Secretary of Defense at the Department of Defense Inspector General, concentrating on the Wounded Warrior Program, BioAssurity and Ebola Outbreak Assessment.



Tom Hubbard

*Vice President, Policy
Research
Network for Excellence in
Health Innovation (NEHI)*

Tom Hubbard works closely with NEHI's 90-plus member organizations from all sectors of U.S. health care, and currently his responsibilities include projects on value-based contracting for pharmaceuticals. Previously he led NEHI projects on medication management and patient medication adherence, comparative effectiveness research policy, and the use of real world evidence in health care decision-making. Tom previously served as Vice President for Technology Development and Analysis at the Massachusetts Technology Collaborative, as well as Executive Assistant for Economic Affairs to U.S. Senator John Kerry, and as Deputy Director of Development for Massachusetts Governor Michael Dukakis. He is a graduate of Harvard College and holds a Master in Public Policy degree from Harvard's Kennedy School of Government.



Michael H. James, JD

Health Care Consulting

Michael H. James in 1994 developed Genesys PHO, an organization based on population care and established with the help of 40 primary care physicians and a health system engaged in managed care with 43,000 commercial risk HMO members. In December 2015, at his retirement, Genesys had 122,000 risk members and managed \$3.8 billion in risk revenue over the 21 years, paying out quality incentives and utilization surpluses every year to participating providers for a total of roughly \$400 million. Throughout those 21 years, Genesys PHO expanded from commercial full risk contracts to Medicaid full risk contracts, Medicare full risk contracts and was one of the original Pioneer ACOs. Michael also was President and CEO of Genesys Integrated Group Practice, a primary care/specialist group practice with 80 physicians and its ancillary health care businesses.



Jim Kenney, RPh, MBA

*Manager, Specialty and
Pharmacy Contracts
Harvard Pilgrim Health Care*

Jim Kenney has held various positions at Harvard Pilgrim during his 36-year tenure, including as Staff Pharmacist, Chief Pharmacist, Assistant Administrator for Pharmacy Programs and Pharmacy Operations Manager. His accomplishments include creation and management of the network pharmacy program for the group practice model of Harvard Pilgrim, development of the pharmacy rebate program, and creation of the Medicare Part D contracting program. Jim also developed the specialty pharmacy program for injectables and a program for supporting infertility management. He currently serves on the Massachusetts Pharmacists Association Government and Legislative Affairs Committee, and is a member of the AMCP Board of Directors.



Only **12%** of global value-based pharmaceutical purchasing agreements happen in the U.S.*

WHAT IS HOLDING THE U.S. BACK?



IDENTIFYING
MEANINGFUL
OUTCOMES



MEASURING
OUTCOMES



ACCESSING
DATA
INFRASTRUCTURE



DEFINING
CONTRACT
TERMS



SELECTING
APPROPRIATE
PATIENTS



EVALUATING
POTENTIAL
RISKS



MANAGING
ONGOING
PERFORMANCE

RXANTE CAN HELP

RxAnte addresses these challenges and enables the creation and ongoing management of value-based purchasing arrangements for both insurers and manufacturers. Our solution includes:

- 1 Drug-level performance analysis**
- 2 Data-driven value-based contract design**
- 3 Ongoing contract performance management and prescribing and adherence interventions**

Source: "Private Sector RSAs in the United States", September 2015 issue of American Journal of Managed Care, Vols. 21, No. 9



To learn more about how RxAnte can assist with value-based purchasing visit www.rxante.com.

FORUM PARTICIPANTS



James R. Lang, PharmD

Vice President of Pharmacy Services

Blue Cross Blue Shield of Michigan

James R. Lang has 30 years of experience managing pharmacy programs, including as a senior executive in settings such as pharmacy benefit management companies, managed care, and hospital systems. Lang served as President of Anthem Prescription Management, where he grew the company from serving two million members to over seven million members. Prior to joining Anthem, he was the President of Healthsource Rx, a subsidiary of Healthsource that provided pharmacy benefit management services for approximately 1.5 million members in fifteen states.



Vinson C. Lee, PharmD, MS, FCPHA, FAMCP

Director, Inflammation Reimbursement, Access & Value

US Value & Access Amgen, Inc.

Vinson Lee develops and oversees the execution of reimbursement, access and value strategy for Amgen's inflammation product portfolio. He currently serves as President of the California Pharmacists Association (CPhA) and serves on the AMCP Organizational Affairs committee. Vinson received his Doctor of Pharmacy from the University of Southern California (USC) School of Pharmacy, Masters of Science in Cell & Neurobiology from the Keck School of Medicine of USC, and Bachelor of Science in Biology from the University of California, Riverside. He was designated Fellow of AMCP in March 2017, received the NCPA/CPhA Pharmacy Leadership Award in February 2017, designated Fellow of CPhA in April 2014, and honored as the 2012 CPhA Distinguished New Practitioner of the Year.



Greg Low, RPh, PhD

Director, Massachusetts General Physicians Organization's (MGPO) Pharmacy Quality and Utilization Program
Massachusetts General Hospital

Greg Low works with MGPO leadership to develop, implement, and evaluate ambulatory pharmacy programs. His current efforts include addressing pharmacy's contribution to total medical expense, physician variation reporting, pay-for-performance and ACO reporting, and academic detailing. He began his training with a BS in Pharmacy from the University of Rhode Island, followed by a residency in clinical informatics with Ohio Northern University. His residency demonstrated the importance of translating electronic clinical data into actionable information, leading Greg to complete a doctorate in pharmacoepidemiology and pharmacoconomics at the University of Rhode Island.



Stephen Northrup, MPA

Founding Partner

Rampy Northrup LLC

Stephen Northrup is a founding partner of Rampy Northrup. Steve puts his diverse experiences and background to use in representing some of the nation's leading health care companies, associations and coalitions. On Capitol Hill, Steve served as the Republican health policy director for the Senate Committee on Health, Education, Labor and Pensions. Prior to his committee tenure, he was chief health policy advisor to Sen. Mike Enzi of Wyoming. After leaving Capitol Hill, Steve served as the head federal lobbyist for one of the nation's leading health benefits companies during the debate over the Affordable Care Act. He then joined the Podesta Group, where he co-chaired the firm's health practice. From 1998 through 2001, Steve was CEO of the Medical Device Manufacturers Association. He has a bachelor's degree from Hamilton College and a master's degree in public administration from George Mason University.



Better Health, Brighter Future

There is more that we can do to help improve people's lives. Driven by passion to realize this goal, Takeda has been providing society with innovative medicines since our foundation in 1781.

Today, we tackle diverse healthcare issues around the world, from prevention to care and cure, but our ambition remains the same to find new solutions that make a positive difference, and deliver medicines that help as many people as we can, as soon as we can.

With our breadth of expertise and our collective wisdom and experience, Takeda will always be committed to improving the future of healthcare.

FORUM PARTICIPANTS



Surya Singh, MD

*Corporate Vice President & CMO, CVS/Specialty
Adjunct Instructor of Medicine, Harvard Medical School*

Surya Singh is responsible for specialty client & clinical strategy, product innovation, analytics and clinical program management. Prior to joining CVSHealth, Surya was Chief Medical Officer and Head of Product Development and Strategy at Proventys, a health care technology firm whose technology was acquired by McKesson Corporation. Before joining Proventys, he was Chief Medical Officer and SVP of Clinical Operations at D2Hawkeye (now part of Verisk Health), and worked as a health care strategy consultant at McKinsey and Company. He continues to care for patients as a Hospitalist at the Brigham and Women's Hospital and is an Adjunct Instructor of Medicine at Harvard Medical School.



Robin Turpin, PhD

*Value Evidence Lead
Takeda*

Robin Turpin's responsibilities include anticipating changes to payment reform/MACRA, value-based insurance design, FDAMA 114, and other transformations that impact payer coverage and reimbursement decisions. She has worked for hospital and health care systems, as well as the Joint Commission on Accreditation of Healthcare Organizations where she led performance metric testing. Her industry experience includes HEOR positions with Merck, Baxter and Takeda. She has co-authored more than 100 books, book chapters, and journal articles on health economics and population health management. She received her PhD in Social Psychology and was a Distinguished Fellow with the National Institute of Disability and Rehabilitation Research. She has held academic appointments with Loyola University Chicago and Northwestern University Medical School, and serves on the editorial board of Population Health Management.



David Uldricks, JD, LLM

*Vice President, PBM
Contracting and Strategy
Employers Health*

David Uldricks is responsible for developing contract terms and conditions of PBM contracts that serve the best interests of a purchasing coalition of more than 175 pharmacy benefit plan sponsors. Prior to joining Employers Health, David worked in the pharmacy benefit management industry, where he was responsible for rebate contracting with pharmaceutical manufacturers and formulary development and management. David also has previous experience in the consulting, insurance and pharmaceuticals industries. He earned his undergraduate degree from Ohio University, and his Juris Doctor and a Master of Laws degree from Capital University Law School.



Harry Vargo

*Pharmacy Director,
Manufacturing Trade Relations
Aetna*

Harry Vargo has primary responsibility for negotiating and executing rebate agreements with pharmaceutical manufacturers in support of commercial and Medicare formularies. In addition, he focuses on developing short- and long-term formulary strategies in concert with key market events. Prior to joining Aetna in 2012, he was owner of Medicap Pharmacy. Other previous positions included Senior Clinical Account Executive, Aetna; Clinical Pharmacy Manager, Express Scripts; and Pharmaceutical Specialist, AdvancePCS. He received his MBA from Eastern University and pharmacy degree from the University of the Sciences in Philadelphia.



INSPIRATION BEGINS WITH YOU

In a marketplace where demands for data and differentiation are high, choose a market access partner that can turn your hard work into an inspiring story.

Choose Xcenda.

With scientific rigor as a foundation, along with innovative thinking and creative expertise, Xcenda helps uncover and transform evidence into an impactful value proposition that matters to payers and maximizes access to your product. Together, let's inspire success.

Visit us at www.xcenda.com



FORUM PARTICIPANTS



Michael P. Wascovich,
PharmD, MBA, RPh

*Senior Director, Pharmacy
Services
Premier*

Mike Wascovich joined Premier in 2015 as Senior Director of Pharmacy Services. Previously he served as Senior Director for ambulatory and specialty pharmacy services at the Cleveland Clinic. Prior to joining the Clinic, Mike served as Officer-in-Charge of hospital pharmacy and outpatient pharmacy at Offutt Air Force Base in Omaha, Nebraska. He received his Baccalaureate in Pharmacy from The Ohio State University, an MBA from Tiffin University and a PharmD from the University of Florida. In addition, he graduated from Officer Training School, Maxwell Air Force Base, U.S. Air Force. He is an active member of American Society of Health System Pharmacy, the American Pharmacists Association (past officer), and AMCP.



Kimberly Westrich, MA

*Vice President, Health
Services Research
National Pharmaceutical
Council (NPC)*

Kimberly Westrich is responsible for leading research initiatives on the value of pharmaceuticals. She has published extensively on issues related to value assessment frameworks, accountable care organizations, clinical pathways, risk-sharing agreements, quality performance measurement, comparative effectiveness research for health care decision-making, and value-based insurance design. Prior to joining NPC, Kimberly served as director of research at PhRMA. She also worked as a health care consultant at the Lewin Group and as a pharmacoeconomic analyst at Johnson & Johnson. Kimberly received her master's degree in economics from Northwestern University and undergraduate degree in economics from the College of William and Mary.



Erik Zbranek

*Director, Portfolio Contracting
& Innovation
Novo Nordisk.*

Erik Zbranek guides Novo Nordisk's strategy for innovative contracting approaches, including value-based contracting efforts. He helps assess key market access challenges for Novo's strategic brands and works with a cross-functional team to develop potential contracting solutions. Prior to joining Novo Nordisk, Erik held various roles in Finance, Pricing and Strategy including most recently at Medco Health Solutions. There he led a team of financial analysts supporting a large drug purchasing coalition focused on providing solutions to manage their drug trend. Erik also helped advance Medco's International presence developing market entry strategies for the major EU markets. Many of these solutions are very similar to the value-based arrangements that we are seeing in the market today. Erik has his MBA in Finance and Strategy from Washington University in St. Louis.

ACADEMY OF MANAGED CARE PHARMACY STAFF

Reginia Benjamin, JD

Director, Legislative Affairs

Susan Cantrell, RPh, CAE

Chief Executive Officer

Mary Jo Carden, RPh, JD

Vice President, Government & Pharmacy Affairs

Judy Crespi-Lofton, MS

Writer, JCL Communications, LLC

Charlie Dragovich, BS Pharm

Senior Director, Strategic Alliances and Business Development

Neal Learner

Media Relations and Editorial Director

Noreen Matthews, BSN, MBA

Program Management, American Medical Communications

Mark Milligan

Vice President, Finance

Terry Richardson, PharmD, BCACP

Director, Product Development

Soumi Saha, PharmD, JD

Director, Pharmacy and Regulatory Affairs

Puneet Singh, PharmD

Education Program Manager

Tricia Lee Wilkins, PharmD, MS, PhD

Director, Pharmacy Affairs

THANK YOU

To our distinguished
participants and guests.

*The Academy of Managed Care
Pharmacy looks forward to holding
more partnership forums focused on
issues of greatest importance to our
8,000 members, the more than 200
million Americans covered by the
pharmacy benefit, and other health
care stakeholders.*





The Academy of Managed Care Pharmacy wishes to thank the following organizations for their generous support of this AMCP Partnership Forum.



Bristol-Myers Squibb



MERCK
INVENTING FOR LIFE



PREMIER



RxAnte
Know the future.
Then change it.®





Academy of
Managed Care
Pharmacy®

675 North Washington Street
Suite 220
Alexandria, VA 22314

Tel 703.684.2600
Fax 703.684.2651
www.amcp.org